Effects of metformin on body weight and body composition in obese insulin-resistant children: A randomized clinical trial

Diabetes

Volumn 60, Issue 2, 2011, Pages 477-485

  Yanovski, Jack A ^a   Krakoff, Jonathan ^b   Salaita, Christine G ^c   McDuffie, Jennifer R ^a   Kozlosky, Merel ^c   Sebring, Nancy G ^c   Reynolds, James C ^c   Brady, Sheila M ^a   Calis, Karim A ^a,c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; METFORMIN;

ARTICLE; BODY COMPOSITION; BODY WEIGHT; CHILD; COMORBIDITY; CONTROLLED STUDY; DIETITIAN; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIQUID FECES; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; OBESITY; OPEN STUDY; PARENT; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION; WEIGHT REDUCTION;

BODY COMPOSITION; BODY WEIGHT; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; OBESITY; TREATMENT OUTCOME;

EID: 79551597310     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1185     Document Type: Article

References (51)

1. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010;303:242-249
2. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-2374 (Pubitemid 38702847)
3. Sun SS, Liang R, Huang TT, et al. Childhood obesity predicts adult metabolic syndrome: the Fels Longitudinal Study. J Pediatr 2008;152:191-200
4. Lee JW, Lee DC, Im JA, Shim JY, Kim SM, Lee HR. Insulin resistance is associated with arterial stiffness independent of obesity in male adolescents. Hypertens Res 2007;30:5-11
5. Skarfors ET, Selinus KI, Lithell HO. Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. BMJ 1991;303: 755-760
6. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001;24:89-94
7. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995;44:1386-1391
8. Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year follow-up of behavioral, family-based treatment for obese children. JAMA 1990;264:2519-2523
9. Savoye M, Shaw M, Dziura J, et al. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA 2007;297:2697-2704
10. McGovern L, Johnson JN, Paulo R, et al. Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab 2008;93:4600-4605
11. Wilfley DE, Stein RI, Saelens BE, et al. Efficacy of maintenance treatment approaches for childhood overweight: a randomized controlled trial. JAMA 2007;298:1661-1673
12. Kalarchian MA, Levine MD, Arslanian SA, et al. Family-based treatment of severe pediatric obesity: randomized, controlled trial. Pediatrics 2009; 124:1060-1068
13. August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: an Endocrine Society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab 2008;93:4576-4599
14. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294-1301 (Pubitemid 121000706)
15. Cigolini M, Bosello O, Zancanaro C, Orlandi PG, Fezzi O, Smith U. Influence of metformin on metabolic effect of insulin in human adipose tissue in vitro. Diabete Metab 1984;10:311-315
16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
17. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998;6:47-53
18. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-554
19. DeFronzo RA, Goodman AM; The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-549
20. Munro JF, MacCuish AC, Marshall A, Wilson EM, Duncan LJ.Weight-reducing effect of diguanides in obese non-diabetic women. BMJ 1969;2:13-15
21. Fontbonne A, Charles MA, Juhan-Vague I, et al.; BIGPRO Study Group. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996;19:920-926
22. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
23. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008; 121:149-157
24. Lütjens A, Smit JL. Effect of biguanide treatment in obese children. Helv Paediatr Acta 1977;31:473-480
25. Lustig RH, Mietus-Snyder ML, Bacchetti P, Lazar AA, Velasquez-Mieyer PA, Christensen ML. Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children. J Pediatr 2006;148:23-29
26. Fu JF, Liang L, Zou CC, et al. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. Int J Obes (Lond) 2007;31:15-22
27. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50:1457-1461
28. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55
29. Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006;91:2074-2080
30. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008;21:339-348
31. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008;152:817-822
32. Burgert TS, Duran EJ, Goldberg-Gell R, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008;9:567-576
33. Wilson DM, Abrams SH, Aye T, et al.; Glaser Pediatric Research Network Obesity Study Group. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med 2010;164:116-123
34. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009;32: 1743-1745
35. Freemark M. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. Diabetes Care 2007;30:395-402
36. Allen HF, Mazzoni C, Heptulla RA, et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2005;18:761-768
37. Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006;160:241-246
38. Ibáñez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab 2006;91:2888-2891
39. Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab 2008;93:1841-1845
40. Epstein LH, Valoski AM, Kalarchian MA, McCurley J. Do children lose and maintain weight easier than adults: a comparison of child and parent weight changes from six months to ten years. Obes Res 1995;3:411-417
41. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003;26:3320-3325
42. Epstein LH, Gordy CC, Raynor HA, Beddome M, Kilanowski CK, Paluch R. Increasing fruit and vegetable intake and decreasing fat and sugar intake in families at risk for childhood obesity. Obes Res 2001;9:171-178 (Pubitemid 33600277)
43. Han JC, Rutledge MS, Kozlosky M, et al. Insulin resistance, hyperinsulinemia, and energy intake in overweight children. J Pediatr 2008;152: 612-617
44. Gustafson JK, Yanoff LB, Easter BD, et al. The stability of metabolic syndrome in children and adolescents. J Clin Endocrinol Metab 2009;94: 4828-4834
45. Corso DM, Pucino F, DeLeo JM, Calis KA, Gallelli JF. Development of a questionnaire for detecting potential adverse drug reactions. Ann Pharmacother 1992;26:890-896
46. Berkowitz RI, Fujioka K, Daniels SR, et al; Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006;145:81-90
47. Cicero AF, Dormi A, Nascetti S, et al. Relative role of major risk factors for type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabet Med 2005;22:1263-1266
48. Al Mamun A, Cramb SM, O'Callaghan MJ, Williams GM, Najman JM. Childhood overweight status predicts diabetes at age 21 years: a follow-up study. Obesity (Silver Spring) 2009;17:1255-1261
49. Hoffman RP. Indices of insulin action calculated from fasting glucose and insulin reflect hepatic, not peripheral, insulin sensitivity in African-American and Caucasian adolescents. Pediatr Diabetes 2008;9: 57-61
50. Tirosh A, Shai I, Tekes-Manova D, et al; Israeli Diabetes Research Group. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005;353:1454-1462
51. Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B (12) deficiency in patients receiving metformin. Arch Intern Med 2006;166: 1975-1979